Login / Signup

Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.

Grace K GrafhamKenneth J CraddockWeei-Yuarn HuangAlexander V LouieLiying ZhangDavid M HwangAmbica Parmar
Published in: Cancer medicine (2024)
Our results demonstrate the advantages of in-house biomarker testing for mNSCLC at a tertiary oncology center. Incorporation of in-house testing may reduce barriers to offering personalized medicine by improving the time to optimal systemic therapy decision.
Keyphrases
  • squamous cell carcinoma
  • small cell lung cancer
  • palliative care
  • stem cells
  • decision making
  • mesenchymal stem cells
  • single molecule
  • medical students
  • drug induced
  • smoking cessation